https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45140 Wed 26 Oct 2022 13:33:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45843 Wed 09 Nov 2022 10:03:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37043 Tue 08 Aug 2023 10:05:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49453 Thu 18 May 2023 11:23:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43444 n = 958) demonstrated that a modular hemiarthroplasty implant conferred no additional benefit over the traditional monoblock implant for quality of life and length of hospital stay. We compared and weighted the trial sample against two target populations: WHiTE-cohort (n = 2,457) and UK-National Hip Fracture Database (NHFD, n = 190,894), and re-estimate expected treatment effects for the target populations. Results: Despite differences in baseline characteristics of the trial sample and target populations, the re-estimated treatment effects were comparable. For quality of life, the differences between the trial estimate and WHiTE-cohort and NHFD estimates were 0.01 points on the EuroQol (EQ5D). For length of stay, the difference between the trial estimate and WHiTE-cohort was 0.50 days; and the difference between the trial estimate and NHFD estimate was −0.47 days. Conclusion: This generalizability analysis of the WHiTE-3 trial found that the inferences from the trial can be generalized to a wider population of individuals in the UK NHFD and the WHiTE-cohort who met the inclusion criteria for WHiTE-3.]]> Mon 19 Sep 2022 14:37:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54101 Mon 05 Feb 2024 09:35:39 AEDT ]]>